Evidence map›Paper›PMID 41737783›Full record

ArticleEJHaem2026

Secondary Chronic Myeloid Leukemia in the Blast Phase With Mixed Phenotype After Radiation Therapy: A Case Report.

Masanori Aoki, Tomoya Maeda, Hiromi Kinoshita, Yoshitada Taji, Daisuke Shintani, Naoki Takahashi, Yasuhiro Ebihara

Abstract read
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Masanori AokiClinical Laboratory Saitama Medical University International Medical Center Saitama Japan.
Tomoya MaedaDepartment of Hemato-Oncology Saitama Medical University International Medical Center Saitama Japan.
Hiromi KinoshitaClinical Laboratory Saitama Medical University International Medical Center Saitama Japan.
Yoshitada TajiClinical Laboratory Saitama Medical University International Medical Center Saitama Japan.
Daisuke ShintaniDepartment of Gynecologic Oncology Saitama Medical University International Medical Center Saitama Japan.
Naoki TakahashiDepartment of Hemato-Oncology Saitama Medical University International Medical Center Saitama Japan.
Yasuhiro EbiharaClinical Laboratory Saitama Medical University International Medical Center Saitama Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 55-year-old woman underwent hysterectomy and pelvic radiation for cervical cancer, which remains in remission. Forty-three months later, she developed secondary CML-BP with CD19+ mixed phenotype (B/myeloid), previously unreported. Following induction therapy, sequential therapy with blinatumomab and ponatinib achieved qualitatively PCR-negative minor

Indexed as

blinatumomabCD19ponatinibsecondary chronic myeloid leukemiathe blast phase with CD19‐expressing mixed phenotype

Identifiers

PMID41737783
PMCPMC12928080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.